Developer docs
API playgroundTry for free, no card

Search company profiles

DropGenie

Full company profile

uuid0005ds7

Namestring
DropGenie
Legal namestring
DropGenie, Inc.
Websiteurl
drop-genie.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

DropGenie is a privately held biotechnology company founded in 2020 that has developed a miniaturized and automated gene editing platform built on patented chips using proprietary electrode configurations driven by electrostatic forces. The platform delivers editing reagents (mRNA, DNA, or proteins) into cells in nanoliter volumes, eliminating pipetting, pumps, and oils, and is compatible with SBS-format lab automation. DropGenie reports 100x miniaturization, 40x lower cost, and 100x faster workflows versus conventional approaches, with demonstrated high-efficiency CRISPR knockout in primary T cells using ~10,000 cells versus the ~1,000,000 cells reportedly required by competing methods.

The company targets three primary use cases: functional genomics screening (to increase screen depth and donor diversity from limited sample material), cell and gene therapy process development (to optimize TCR and CAR-immune cell candidate selection from small patient populations), and AI-driven drug discovery (to generate positive and negative functional validation data at scale for AI-predicted hits). The company commercializes through direct sales to biopharma and cell therapy buyers via 'Get Early Access' and 'Request Demo' CTAs, supplemented by industry conference presence (SLAS, ASGCT), scientific content (case studies with Sartorius and Beckman Coulter), webinars, and earned media. Pricing is not publicly disclosed and is structured as quote-based enterprise sales.

DropGenie operates from Cambridge, MA (US headquarters) and Montreal, QC (Canada), has 11-50 employees, and is backed by a syndicate led by Skeleton Key with participation from Merck Global Health Innovation Fund, CQDM, Real Ventures, and Anges Québec in a June 2026 Seed+ round. The company was also selected into the March 2026 cohort of Merck's Digital Sciences Studio accelerator. Leadership comprises co-founders Alison Hirukawa (CEO), Philippe Vo (Head of Software), and Hugo Sinha (COO).

Short descriptiontext

DropGenie commercializes a patented, electrostatic chip-based platform that miniaturizes and automates gene editing workflows for biopharma, cell therapy developers, and AI drug discovery researchers, enabling high-throughput CRISPR screens in nanoliter volumes.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene editing platform, cell engineering automation, microfluidic screening tools, CRISPR screening reagents, lab automation instruments
Industry3 codes
PRIMARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Research and Development in Nanotechnology541713
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cell Engineering Automation
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Editing Platform and Reagents
TypeHardware Sales
Description

DropGenie commercializes its miniaturized gene editing platform, including associated reagents and consumables, to biopharma companies, cell therapy developers, and functional genomics researchers. The company is scaling manufacturing and building commercial operations following its Seed+ financing.

pulse2.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

DropGenie sells a miniaturized, automated gene editing platform built on patented chips that use proprietary electrode configurations driven by electrostatic forces to deliver any editing reagent (mRNA, DNA, or proteins) into any cell type in nanoliter volumes. The platform includes the chip hardware, associated reagents and consumables, and SBS-format-compatible automation for high-throughput arrayed CRISPR screening and cell engineering workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100x miniaturization — do more with less, ideal for scarce samples
+3 more records
Product overview1 text field

DropGenie offers a unified lab automation platform that miniaturizes and parallelizes gene editing workflows on patented chips. The platform enables high-throughput, low-volume cell engineering reactions using proprietary electrode configurations and electrical parameter tuning to deliver any cargo (mRNA, DNA, or proteins) into any cell type. The system features direct cargo printing, adaptive tuning for each experimental condition, and modular SBS-format compatibility for integration with existing lab automation. Key applications include functional genomics screening, cell and gene therapy process development, and AI-driven drug discovery validation.

Product and service1 record
1DropGenie Gene Editing Platform
CategoryCell Engineering Automation
Description

Miniaturized and automated gene editing platform built on patented chips that use proprietary electrode configurations driven by electrostatic forces to deliver editing reagents (mRNA, DNA, proteins) into cells in nanoliter volumes. Includes the chip hardware, adaptive electrical tuning, direct cargo printing, and SBS-format compatibility for integration with existing lab automation, sold to biopharma, cell therapy, and functional genomics customers for arrayed CRISPR screening and cell engineering.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

DropGenie was selected into the second cohort of Merck's Digital Sciences Studio accelerator in Montreal, Canada (March 2026). The nine-month program provides $100,000 USD in funding, mentorship from Merck scientists, and operating support from Centech. The program supports digital technologies in biopharma including AI solutions and is part of a consortium including Merck Global Health Innovation Fund, The Venture Collective, and CQDM.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Sartorius is a major life sciences lab automation and bioprocessing supplier and a published DropGenie integration partner. The two companies co-market integrated workflows, so they are simultaneously partners and indirect competitors for the same workflow budgets.

TypeDirect peer
Description

Standard BioTools builds microfluidic and chip-based life sciences instrumentation (e.g., IFC-based controllers) for single-cell and genomics workflows — the closest analog to DropGenie's chip-based electrostatic platform in miniaturization philosophy.

TypeEmerging player
Description

Element Biosciences develops next-generation sequencing and multi-omics platforms, giving functional genomics and drug discovery researchers an alternative workflow adjacent to DropGenie's screening platform.

TypeBroad incumbent
Description

10x Genomics sells broadly adopted single-cell and functional genomics platforms that compete for the same functional genomics and cell therapy research budget, though it does not directly offer gene editing delivery.

TypeBroad incumbent
Description

Thermo Fisher is the largest life sciences tools vendor with broad portfolios spanning cell engineering, CRISPR reagents, and lab automation — a broad incumbent whose installed base sets the standard against which new entrants like DropGenie must differentiate.

TypeBroad incumbent
Description

Bio-Rad supplies a broad portfolio of life sciences research tools, including droplet-based digital PCR and cell biology reagents that compete for the same functional genomics and gene editing research spend.

TypeDirect peer
Description

PhenomeX (formerly Berkeley Lights) markets optofluidic cell biology automation platforms that engineer and analyze single cells — competing in the same single-cell / high-throughput functional screening arena DropGenie targets.

8CytoVerdict (or comparable cell-engineering startup)
TypeEmerging player
Description

CytoVerdict (and similar single-cell / cell-engineering startups) target portions of the same functional genomics and cell therapy R&D workflow as DropGenie, representing emerging competition from lower-cost entrants with overlapping but narrower offerings.

TypeEmerging player
Description

Mission Bio provides single-cell multi-omics and genomics tools (e.g., Tapestri) used by CGT developers and functional genomics researchers, partially overlapping with DropGenie's genomic screening applications.

TypeDirect peer
Description

MaxCyte commercializes electroporation-based cell engineering platforms used by biopharma and cell therapy developers for CRISPR delivery and gene editing workflows — directly overlapping with DropGenie's core CGT and functional genomics use cases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DropGenie

Cell Engineering Automationdrop-genie.com

DropGenie commercializes a patented, electrostatic chip-based platform that miniaturizes and automates gene editing workflows for biopharma, cell therapy developers, and AI drug discovery researchers, enabling high-throughput CRISPR screens in nanoliter volumes.

What DropGenie does

DropGenie is a privately held biotechnology company founded in 2020 that has developed a miniaturized and automated gene editing platform built on patented chips using proprietary electrode configurations driven by electrostatic forces. The platform delivers editing reagents (mRNA, DNA, or proteins) into cells in nanoliter volumes, eliminating pipetting, pumps, and oils, and is compatible with SBS-format lab automation. DropGenie reports 100x miniaturization, 40x lower cost, and 100x faster workflows versus conventional approaches, with demonstrated high-efficiency CRISPR knockout in primary T cells using ~10,000 cells versus the ~1,000,000 cells reportedly required by competing methods.

The company targets three primary use cases: functional genomics screening (to increase screen depth and donor diversity from limited sample material), cell and gene therapy process development (to optimize TCR and CAR-immune cell candidate selection from small patient populations), and AI-driven drug discovery (to generate positive and negative functional validation data at scale for AI-predicted hits). The company commercializes through direct sales to biopharma and cell therapy buyers via 'Get Early Access' and 'Request Demo' CTAs, supplemented by industry conference presence (SLAS, ASGCT), scientific content (case studies with Sartorius and Beckman Coulter), webinars, and earned media. Pricing is not publicly disclosed and is structured as quote-based enterprise sales.

DropGenie operates from Cambridge, MA (US headquarters) and Montreal, QC (Canada), has 11-50 employees, and is backed by a syndicate led by Skeleton Key with participation from Merck Global Health Innovation Fund, CQDM, Real Ventures, and Anges Québec in a June 2026 Seed+ round. The company was also selected into the March 2026 cohort of Merck's Digital Sciences Studio accelerator. Leadership comprises co-founders Alison Hirukawa (CEO), Philippe Vo (Head of Software), and Hugo Sinha (COO).

DropGenie firmographics

Firmographics
Name
DropGenie
Legal name
DropGenie, Inc.
Website
https://drop-genie.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
DropGenie commercializes a patented, electrostatic chip-based platform that miniaturizes and automates gene editing workflows for biopharma, cell therapy developers, and AI drug discovery researchers, enabling high-throughput CRISPR screens in nanoliter volumes.
Ownership category
akta.pro rank

DropGenie industry classification

Industry
Product category
Cell Engineering Automation
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Nanotechnology (541713)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)

Keywords

  • Gene editing platform
  • Cell engineering automation
  • Microfluidic screening tools
  • CRISPR screening reagents
  • Lab automation instruments

Where DropGenie is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

DropGenie business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Gene Editing Platform and Reagents: DropGenie commercializes its miniaturized gene editing platform, including associated reagents and consumables, to biopharma companies, cell therapy developers, and functional genomics researchers. The company is scaling manufacturing and building commercial operations following its Seed+ financing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

DropGenie product offering

Product offering

Core offering

DropGenie sells a miniaturized, automated gene editing platform built on patented chips that use proprietary electrode configurations driven by electrostatic forces to deliver any editing reagent (mRNA, DNA, or proteins) into any cell type in nanoliter volumes. The platform includes the chip hardware, associated reagents and consumables, and SBS-format-compatible automation for high-throughput arrayed CRISPR screening and cell engineering workflows.

Product overview

DropGenie offers a unified lab automation platform that miniaturizes and parallelizes gene editing workflows on patented chips. The platform enables high-throughput, low-volume cell engineering reactions using proprietary electrode configurations and electrical parameter tuning to deliver any cargo (mRNA, DNA, or proteins) into any cell type. The system features direct cargo printing, adaptive tuning for each experimental condition, and modular SBS-format compatibility for integration with existing lab automation. Key applications include functional genomics screening, cell and gene therapy process development, and AI-driven drug discovery validation.

Differentiator

Problem solved

Functional benefit

Products and services

  • DropGenie Gene Editing Platform Miniaturized and automated gene editing platform built on patented chips that use proprietary electrode configurations driven by electrostatic forces to deliver editing reagents (mRNA, DNA, proteins) into cells in nanoliter volumes. Includes the chip hardware, adaptive electrical tuning, direct cargo printing, and SBS-format compatibility for integration with existing lab automation, sold to biopharma, cell therapy, and functional genomics customers for arrayed CRISPR screening and cell engineering.

Quantifiable outcome

  • 100x miniaturization — do more with less, ideal for scarce samples
  • +3 more outcomes

Companies that use DropGenie

Customer profile

Segments3 records

Ideal customer profiles3 records

DropGenie technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

DropGenie partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Merck Digital Sciences Studio (MDSS)coreStrategic or Co-development Partner · 1 March 2026DropGenie was selected into the second cohort of Merck's Digital Sciences Studio accelerator in Montreal, Canada (March 2026). The nine-month program provides $100,000 USD in funding, mentorship from Merck scientists, and operating support from Centech. The program supports digital technologies in biopharma including AI solutions and is part of a consortium including Merck Global Health Innovation Fund, The Venture Collective, and CQDM.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

DropGenie competitors and assessment

Company assessment

Broad incumbents

  • Sartorius: Sartorius is a major life sciences lab automation and bioprocessing supplier and a published DropGenie integration partner. The two companies co-market integrated workflows, so they are simultaneously partners and indirect competitors for the same workflow budgets.
  • 10x Genomics: 10x Genomics sells broadly adopted single-cell and functional genomics platforms that compete for the same functional genomics and cell therapy research budget, though it does not directly offer gene editing delivery.
  • Thermo Fisher Scientific: Thermo Fisher is the largest life sciences tools vendor with broad portfolios spanning cell engineering, CRISPR reagents, and lab automation — a broad incumbent whose installed base sets the standard against which new entrants like DropGenie must differentiate.
  • Bio-Rad Laboratories: Bio-Rad supplies a broad portfolio of life sciences research tools, including droplet-based digital PCR and cell biology reagents that compete for the same functional genomics and gene editing research spend.

Direct peers

  • Standard BioTools (formerly Fluidigm): Standard BioTools builds microfluidic and chip-based life sciences instrumentation (e.g., IFC-based controllers) for single-cell and genomics workflows — the closest analog to DropGenie's chip-based electrostatic platform in miniaturization philosophy.
  • Berkeley Lights (now PhenomeX): PhenomeX (formerly Berkeley Lights) markets optofluidic cell biology automation platforms that engineer and analyze single cells — competing in the same single-cell / high-throughput functional screening arena DropGenie targets.
  • MaxCyte: MaxCyte commercializes electroporation-based cell engineering platforms used by biopharma and cell therapy developers for CRISPR delivery and gene editing workflows — directly overlapping with DropGenie's core CGT and functional genomics use cases.

Emerging players

  • Element Biosciences: Element Biosciences develops next-generation sequencing and multi-omics platforms, giving functional genomics and drug discovery researchers an alternative workflow adjacent to DropGenie's screening platform.
  • CytoVerdict (or comparable cell-engineering startup): CytoVerdict (and similar single-cell / cell-engineering startups) target portions of the same functional genomics and cell therapy R&D workflow as DropGenie, representing emerging competition from lower-cost entrants with overlapping but narrower offerings.
  • Mission Bio: Mission Bio provides single-cell multi-omics and genomics tools (e.g., Tapestri) used by CGT developers and functional genomics researchers, partially overlapping with DropGenie's genomic screening applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

DropGenie social profiles

Digital presence

DropGenie financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DropGenie leadership team

Management profile

Number of profiles

Profiles4 records

DropGenie funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DropGenie M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DropGenie

What does DropGenie do?

DropGenie sells a miniaturized, automated gene editing platform built on patented chips that use proprietary electrode configurations driven by electrostatic forces to deliver any editing reagent (mRNA, DNA, or proteins) into any cell type in nanoliter volumes. The platform includes the chip hardware, associated reagents and consumables, and SBS-format-compatible automation for high-throughput arrayed CRISPR screening and cell engineering workflows.

Is DropGenie a public or private company?

DropGenie is a private company. It is classified as venture growth investor backed and is currently operating.

When was DropGenie founded?

DropGenie was founded in 2020. It employs 11 to 50 people.

Where is DropGenie based?

DropGenie is headquartered in Boston, United States, in the North America region.

How does DropGenie make money?

One revenue line is on record: gene Editing Platform and Reagents.

Who are DropGenie's main competitors?

Broad incumbents on record are Sartorius, 10x Genomics, Thermo Fisher Scientific and Bio-Rad Laboratories. Direct peers are Standard BioTools (formerly Fluidigm), Berkeley Lights (now PhenomeX) and MaxCyte. Emerging players are Element Biosciences, CytoVerdict (or comparable cell-engineering startup) and Mission Bio.

Does DropGenie have an API?

No public API is recorded for DropGenie.

What industry is DropGenie in?

DropGenie's product category is Cell Engineering Automation. Its primary akta.pro industry code is HLAAAIAG, CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq), with a secondary code of HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Startup ResearcherDropGenie Raises $5 Million Seed+ FinancingDropGenie raised $5 million in seed+ financing from BDC Thrive Venture Fund and others. The capital will accelerate commercialization of its automated microfluidic platform, which miniaturizes gene editing workflows. A broader rollout is planned early next year.citybizDropGenie Raises $5M in Seed+ Financing to Expand Drug Discovery PlatformDropGenie raised $5 million in seed+ financing from BDC Thrive Venture Fund and Skeleton Key to expand its automated gene-editing platform. The funding will support commercialization of its first product, which uses up to 100 times fewer cells than conventional workflows. The company plans a broader rollout in early 2027.FinSMEsDropGenie Raises $5M in Seed+ FundingDropGenie, a Cambridge, MA-based functional biology company, raised $5M in seed+ funding from BDC Thrive Venture Fund, Skeleton Key, Merck Global Health Innovation Fund, CQDM, Real Ventures, and Anges Quebec. The company will use the funds to accelerate commercialization of its first product, expand customer engagement, and grow its global footprint.BetaKitDropGenie raises $5 million USD backed by BDC to speed up biological discoveryDropGenie raised $5 million in seed-plus financing led by Skeleton Key, with BDC Capital's Thrive Fund participating. The biotech aims to commercialize its first product, a gene-editing chip using 100 times fewer cells, with a launch planned for Q2 next year.PR NewswireDropGenie Secures $5 Million Seed+ Financing to Scale Functional Biology Platform and Data PartnershipsDropGenie secured $5 million in Seed+ financing from BDC Thrive Venture Fund and others. The funding accelerates commercialization of its first product, which miniaturizes gene editing workflows using up to 100 times fewer cells. The company is expanding services and data partnerships ahead of a broader rollout early next year.News-MedicalStreamlining CRISPR workflows, from editing to analysisINTEGRA collaborated with DropGenie and QUiCKR to automate CRISPR gene editing and analysis workflows. DropGenie's platform reduces cell input by 100x, while QUiCKR's assay quantifies edits in 20 minutes. The webinar on October 8 will cover these solutions.citybizDropGenie Secures Seed+ Funding to Launch Gene Editing PlatformDropGenie, a Montreal- and Boston-based biotechnology company, has closed a Seed+ financing round led by Skeleton Key with participation from Merck Global Health Innovation Fund and CQDM to support the commercial launch of its gene editing platform. The funding will enable the company to scale production capabilities, expand customer engagement efforts, and support broader deployment of its technology across life sciences research organizations. The platform improves the efficiency of gene editing experiments by miniaturizing workflows and reducing cell and reagent requirements, enabling researchers to work directly with primary patient cells and generate more biologically relevant data for cell therapy development, functional genomics, and AI-enabled drug discovery.Pulse 2.0DropGenie Raises Seed+ Financing To Accelerate First Product LaunchDropGenie, a biotechnology company developing miniaturized gene editing workflows, announced the closing of its Seed+ financing round led by Skeleton Key, with participation from new investors Merck Global Health Innovation Fund and CQDM, along with existing investors Real Ventures and Anges Québec. The funding will support commercialization of DropGenie's first product, including scaling manufacturing, building commercial operations, and accelerating customer adoption. The company's platform enables high-throughput gene editing with reduced cell and reagent requirements, targeting applications in cell therapy, functional genomics, and AI-driven discovery, with operations in Montreal and Boston.PR NewswireDropGenie Raises Seed+ Financing to Accelerate Commercialization of Its First ProductDropGenie, a biotechnology company advancing next-generation gene editing workflows, announced the closing of its Seed+ financing round led by Skeleton Key, with participation from Merck Global Health Innovation Fund, CQDM, Real Ventures, and Anges Québec. The funding will support commercialization of DropGenie's first product, including scaling manufacturing, building commercial operations, and accelerating customer adoption following successful validation through its Early Access Program with major global pharma, biotech, and research customers. The company's platform enables high-throughput, miniaturized gene editing workflows that reduce cells and reagents required per experiment, enabling direct edits on primary patient cells for more biologically relevant R&D insights.FinSMEsDropGenie Closes Seed+ FinancingDropGenie, a biotechnology company, raised an undisclosed Seed+ funding round led by Skeleton Key, with participation from Merck Global Health Innovation Fund, CQDM, Real Ventures, and Anges Québec. The company will use the funds to scale manufacturing, build commercial operations, and accelerate customer adoption.